139 related articles for article (PubMed ID: 3303928)
1. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Effect of successful tumor resection on mineral homeostasis.
Reid IR; Teitelbaum SL; Dusso A; Whyte MP
Am J Med; 1987 Aug; 83(2):350-4. PubMed ID: 3303928
[TBL] [Abstract][Full Text] [Related]
2. Tumor-induced osteomalacia. Kinetics of calcium, phosphorus, and vitamin D metabolism and characteristics of bone histomorphometry.
Siris ES; Clemens TL; Dempster DW; Shane E; Segre GV; Lindsay R; Bilezikian JP
Am J Med; 1987 Feb; 82(2):307-12. PubMed ID: 3812526
[TBL] [Abstract][Full Text] [Related]
3. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes.
Zimering MB; Caldarella FA; White KE; Econs MJ
Endocr Pract; 2005; 11(2):108-14. PubMed ID: 15901526
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis.
Weinstein RS; Harris RL
Calcif Tissue Int; 1990 Jun; 46(6):361-6. PubMed ID: 2114209
[TBL] [Abstract][Full Text] [Related]
5. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery.
Elston MS; Stewart IJ; Clifton-Bligh R; Conaglen JV
Bone; 2007 Jan; 40(1):236-41. PubMed ID: 16982223
[TBL] [Abstract][Full Text] [Related]
6. Tumor-induced osteomalacia: a case report.
Romualdo-Silva DD; Silva BC; Caetano CV; Tibúrcio AM; Nunes MB; Chagas SA; Polito ET; Ferreira AR; Purisch S
Arq Bras Endocrinol Metabol; 2009 Apr; 53(3):378-82. PubMed ID: 19578602
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bone density outcomes of tumor-induced osteomalacia after treatment.
Umphrey LG; Whitaker MD; Bosch EP; Cook CB
Endocr Pract; 2007 Sep; 13(5):458-62. PubMed ID: 17872346
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic osteomalacia associated with a mesenchymal chondrosarcoma.
Stone E; Bernier V; Rabinovich S; From GL
Clin Invest Med; 1984; 7(3):179-85. PubMed ID: 6518684
[TBL] [Abstract][Full Text] [Related]
9. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases.
Firth RG; Grant CS; Riggs BL
Am J Med; 1985 Apr; 78(4):669-73. PubMed ID: 2984933
[TBL] [Abstract][Full Text] [Related]
10. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia.
Huang QL; Feig DS; Blackstein ME
J Endocrinol Invest; 2000 Apr; 23(4):263-7. PubMed ID: 10853715
[TBL] [Abstract][Full Text] [Related]
11. Evidence for secondary hyperparathyroidism in the osteomalacia associated with chronic liver disease.
Dibble JB; Sheridan P; Hampshire R; Hardy GJ; Losowsky MS
Clin Endocrinol (Oxf); 1981 Oct; 15(4):373-83. PubMed ID: 6274546
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity.
Miyauchi A; Fukase M; Tsutsumi M; Fujita T
J Clin Endocrinol Metab; 1988 Jul; 67(1):46-53. PubMed ID: 2837500
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and immunohistopathologic study of phosphaturic mesenchymal tumor].
Li DM; Wu HW; Li JD; Xia WB; Jiang Y; Zhong DR
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):427-431. PubMed ID: 29886586
[No Abstract] [Full Text] [Related]
15. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
16. [Sporadic adult hypophosphatemic vitamin D resistant osteomalacia (phosphate diabetes) and hyperparathyroidism].
Kistler HJ; Bonetti A; Frey P; Fischer JA
Schweiz Med Wochenschr; 1976 Dec; 106(51):1855-62. PubMed ID: 1013714
[TBL] [Abstract][Full Text] [Related]
17. Phosphaturic mesenchymal tumor, mixed connective tissue variant (oncogenic osteomalacia).
Tsujimura T; Sakaguchi K; Aozasa K
Pathol Int; 1996 Mar; 46(3):238-41. PubMed ID: 10846577
[TBL] [Abstract][Full Text] [Related]
18. Effects of tumor-induced osteomalacia on the bone mineralization process.
Nawrot-Wawrzyniak K; Varga F; Nader A; Roschger P; Sieghart S; Zwettler E; Roetzer KM; Lang S; Weinkamer R; Klaushofer K; Fratzl-Zelman N
Calcif Tissue Int; 2009 Apr; 84(4):313-23. PubMed ID: 19219382
[TBL] [Abstract][Full Text] [Related]
19. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.
Folpe AL; Fanburg-Smith JC; Billings SD; Bisceglia M; Bertoni F; Cho JY; Econs MJ; Inwards CY; Jan de Beur SM; Mentzel T; Montgomery E; Michal M; Miettinen M; Mills SE; Reith JD; O'Connell JX; Rosenberg AE; Rubin BP; Sweet DE; Vinh TN; Wold LE; Wehrli BM; White KE; Zaino RJ; Weiss SW
Am J Surg Pathol; 2004 Jan; 28(1):1-30. PubMed ID: 14707860
[TBL] [Abstract][Full Text] [Related]
20. Oncogenous osteomalacia: a new case secondary to a malignant tumor.
Rico H; Fernandez-Miranda E; Sanz J; Gomez-Castresana F; Escriba A; Hernandez ER; Krsnik I
Bone; 1986; 7(5):325-9. PubMed ID: 3024684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
